Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Paramount BioCapital Asset Management

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 5
Average round size
info
The average size of a deal this fund participated in
$15M
Portfolio companies 5
Rounds per year 0.36
Lead investments 1
Exits 5
Key employees 1

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Therapeutics
  • Genetics
Summary

The leading representative office of defined VC is situated in the New York. The fund was located in North America if to be more exact in United States.

Moreover, a startup needs to be at the age of 11-15 years to get the investment from the fund. The fund has exact preference in some founders of portfolio startups. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight CEL-SCI, Innovive Pharmaceuticals, Chelsea Therapeutics International. We can highlight the next thriving fund investment areas, such as Medical, Biopharma.

The usual cause for the fund is to invest in rounds with 3-4 partakers. The meaningful sponsors for the fund in investment in the same round are Whalehaven Capital Fund, Rockmore Capital, Ramius Capital. In the next rounds fund is usually obtained by Venrock.

Besides them, we counted 1 critical employee of this fund in our database.

The higher amount of exits for fund were in 2008. The real fund results show that this VC is 5 percentage points more often commits exit comparing to other companies. This Paramount BioCapital Asset Management works on 71 percentage points more the average amount of lead investments comparing to the other organizations. The top activity for fund was in 2009. The fund is constantly included in less than 2 investment rounds annually. Deals in the range of 10 - 50 millions dollars are the general things for fund.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Paramount BioCapital Asset Management:
There are no funds here. If we find new data, we will add it here.
Typical Co-investors
Paramount BioCapital Asset Management is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Paramount BioCapital Asset Management:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Accel India Bangalore, India, Karnataka
AI Music England, Kent, United Kingdom
Brockhaus Private Equity Frankfurt, Germany, Hessen
Chaotic Investments California, Los Angeles, United States
Davidson Capital Group Florida, Santa Rosa Beach, United States
FedDev Canada, Ontario, Waterloo
Femmes Business Angels France, Ile-de-France, Paris
Fushia Investments -
Garuda Ventures California, San Francisco, United States
Hangzhou Trust China, Hangzhou, Zhejiang
Innovations and Future Creation Japan, Tokyo
Proxima Ventures Ltd Israel, Tel Aviv, Tel Aviv District
Purity Star -
Ridge Capital Moscow, Moscow, Russia
Sumin Investment -
Tangel Publishing Changsha, China, Jiangsu
Topspin Fund -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

CEL-SCI

Biotechnology
Health Care
Medical
$4M20 Aug 2009 Virginia, United States

Innovive Pharmaceuticals

Biotechnology
Health Care
Pharmaceutical
$15M25 Apr 2007 New York, New York, United States

Genelabs Technologies

Biopharma
Biotechnology
Health Care
Therapeutics
$8M27 Jun 2006 Redwood City, California, United States

Ziopharm oncology

Biotechnology
Genetics
Pharmaceutical
Therapeutics
$37M03 May 2006 New York, New York, United States

Chelsea Therapeutics International

Biotechnology
Health Care
Pharmaceutical
$14M12 Jan 2005 Charlotte, North Carolina, United States

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Paramount BioCapital Asset Management?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: